NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) (“NeuroScientific” or “the Company”)
is pleased to advise that the Company has filed a Pre-Investigation New Drug Application (‘pre
IND’) meeting request with the US Food and Drug Administration (‘FDA’) for EmtinB for
treatment of advanced glaucoma in adults. The request includes an overview of the proposed
non-clinical and clinical programs in glaucoma, as well as specific questions relating to
regulatory requirements for progression to the filing of an investigational new drug (‘IND’)
application. NeuroScientific expects the meeting to be held within 60 days.
emtinb close to glaucoma nerve cure
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.007(12.7%) |
Mkt cap ! $6.941M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.3¢ | 4.8¢ | $11.88K | 243.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 67118 | 3 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.3¢ |
Change
-0.007 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.3¢ | 5.3¢ | 257 | ||
| Last updated 10.57am 06/05/2024 ? | |||||
| NSB (ASX) Chart |